Cartana secures $1M for a tech platform understanding the brain and its diseases.

Sweden Investments 09 October 2018
Share on FacebookShare on Twitter

Cartana, a Stockholm, Sweden-based company working on a digital platform for brain cell analysis, announced in a press release securing SEK 9.6M ($1M) in capital investment.

The money was provided by a group of Swedish investors via Sciety and includes a SEK 3M contribution from Almi Invest. The funding will be used for further development of the product and market launch.

Cartana, founded in 2017 and led by CEO Malte K├╝hnemund, developed NeuroKit, an optimized reagent kit that enables the mapping of hundreds of genes and cell types via In Situ Sequencing (ISS) in a single tissue section with high throughput and high sensitivity. The solution enables simultaneous analysis of hundreds of genes within all cells comprising a tissue, without losing tissue morphology, with high sensitivity and throughput.